Real-world therapeutic performance of pirfenidone for connective tissue disease-associated interstitial lung diseases.

ABSTRACT:

Background

Pirfenidone (PFD) is commonly applied for antifibrotic treatment in patients with idiopathic pulmonary fibrosis but has rarely been studied in cases with connective tissue disease-associated interstitial lung diseases (CTD-ILDs).

Objectives

We aimed to examine the efficacy of PFD in patients with CTD-ILD based on real-world data.

Design

A retrospective cohort study.

Methods

This study assessed the clinical features of CTD-ILD patients with or without a 6-month PFD treatment. A linear mixed effects model was employed to evaluate the effectiveness of PFD in alleviating lung function changes. Differences in response to PFD were analyzed based on CTD subtype, imaging classification, and pattern of pulmonary function at baseline.

Results

A total of

SUBMITTER: Yuan X 

PROVIDER: S-EPMC11544659 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature